favipiravir (Avigan)

^[1]^[2]^[3]

Indications

used to treat influenza in Japan
Ebola virus (Ebola hemorrhagic fever)
- effective in treating some Ebola-infected patients in a preliminary study
- may reduce mortality in patients with low-to-moderate levels of Ebola virus in the blood (15% vs 30%)
- no benefit in patients with high viral levels
- may be useful for post-exposure prophylaxis^[2]
approved in Russia for treatment of Covid-19^[3]

↑ Young K, Sofair A, Chavey WE Favipiravir Shows Some Promise in Early Ebola Study Physician's First Watch, Feb 6, 2015 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
↑ ^2.0 ^2.1 Jacobs M et al Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infectious Disease. Aug 25, 2015 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26321189 <Internet> http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2815%2900228-5/abstract
↑ ^3.0 ^3.1 Bergman SJ COVID-19 Treatment: Investigational Drugs and Other Therapies. Mesdcape. August 18, 2021 https://emedicine.medscape.com/article/2500116-overview